Bayer’s Response to “Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis”
2010 ◽
Vol 69
(3)
◽
pp. 317-318
◽
Keyword(s):
2015 ◽
Vol 37
(8)
◽
pp. e8-e9
◽